



ISA  2022

XVIII. International Symposium on Amyloidosis 4th – 8th September 2022 | Heidelberg

08.07.2022

Topic Session			Speaker	Presentation Title
Sunday, 4th Sept. 2022				
2:00 PM	4:30 PM	Registration opens		
4:30 PM	5:00 PM	Opening Ceremony	Hegenbart, Ute Palladini, Giovanni Schönland, Stefan Weyand, Cornelia	
5:00 PM	6:30 PM	Keynote Lecture & Opening Lectures	Otzen, Daniel Merlini, Giampaolo Gillmore, Julian	Aging (of the Immune System) Functional Amyloid AL Amyloidosis model - leading the way to cure Gene Therapy in ATTR
6:30 PM	8:00 PM	Welcome Reception		
Monday, 5th Sept. 2022				
7:15 AM	8:30 AM	IKMG - ISA Scientific Meeting	Hegenbart, Ute Leung, Nelson Bridoux, Frank Dispenzler, Angela Herrera, Guillermo	Differential diagnosis of MGRS Treatment endpoints in MGRS MGRS: directions for future research
7:30 AM	8:30 AM	Satellite Symposium Global Bridges		tbc
8:30 AM	10:05 AM	1. Scientific Session	Ricagno, Stefano Ramirez-Alvarado, Marina Zhou, Ping Nikolaou, Panagiota-Efstathia Berghaus, Natalie Schreiner, Sarah Cascino, Pasquale Nevone, Alice Herrera, Guillermo A. Edwards, Camille Vanessa	Next Generation Sequencing Identifies AL-related IGLV Genes in Patients with λ -isotype MGUS or Smoldering Multiple Myeloma Elucidation of the cardiotoxicity of full-length light chains derived from patients with cardiac light chain amyloidosis in comparison to other plasma cell dyscrasias Investigation of IGLV2-14 AL amyloidosis and multiple myeloma light chain sequences Sequence diversity of the kappa light chains from patients with AL amyloidosis and multiple myeloma Single Molecule Real-Time Sequencing of the M protein (SMaRT M-Seq): toward personalized medicine approaches in monoclonal gammopathies An N-glycosylation hotspot in immunoglobulin k light chains is associated with AL amyloidosis Amyloidogenesis by mesangial cells involves active participation of lysosomes Mapping and modelling the molecular mechanisms that drive amyloidogenic light chain induced cardiotoxicity
10:05 AM	10:30 AM	Break / Speaker Corner		
10:30 AM	12:05 PM	2. Scientific Session	Damy, Thibaud Maurer, Matthew Grogan, Martha Witteles, Ronald Masri, Ahmad Fajardo, Johana Rocío Samuels, Leo C Basdavanos, Alyssa Milani, Paolo Razvi, Yousuf	Long-term tafamidis treatment reduces the decline in quality of life among patients with transthyretin amyloid cardiomyopathy Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy Long-term safety and tolerability of acoramidis (AG10) in symptomatic transthyretin amyloid cardiomyopathy: Updated analysis from an ongoing phase 2 open-label extension study Chronic Intravenous Inotropic Therapy in Cardiac Amyloidosis Tolerability and side-effects of therapy in an open-label trial of inotersen for transthyretin amyloid cardiomyopathy Looking over your shoulder to catch amyloidosis earlier: shoulder pathologies are significantly more prevalent in patients with transthyretin cardiac amyloidosis SARS-CoV-2 infection in systemic amyloidosis: the International Society of Amyloidosis' survey Cardiac Transplantation in Transthyretin Amyloid Cardiomyopathy: Outcomes from Three Decades of Tertiary Centre Experience
12:05 PM	1:25 PM	Lunch & Poster Viewing		
1:25 PM	3:05 PM	3. Scientific Session	Wechalekar, Ashutosh Dorbala, Sharmila Martin, Emily Wall, Jonathan Ioannou, Adam Tingen, Hendrea S.A. Rauf, Muhammad Umair Falk, Rodney H Poncelet, Anysla Brandelik, Simone Christine Carpinteiro, Alexander Westermark, Gunilla Sirac, Christophe Simons, Paul Diomedea, Luisa	Amyloid Imaging Cardiac Imaging Pan-amyloid reactivity of radioiodinated peptide 124I-AT-01 in patients with systemic amyloidosis demonstrated by PET/CT imaging Results of the first-in-human PET/CT imaging study of the amyloid-reactive peptide 124I-AT-01 (124I-p5+14) for the detection of systemic amyloidosis Tracking multi-organ treatment response in systemic AL-amyloidosis with cardiac magnetic resonance derived extracellular volume mapping Regression of Cardiac Bone-Tracer Uptake in Patients with Hereditary Transthyretin Amyloidosis after One Year Treatment with Patisiran. An early Marker of Treatment Response? Real World Experience of Tc-DPD scintigraphy as a diagnostic imaging tool in amyloidosis Assessing left ventricular strain in cardiac amyloidosis: the importance of accurate measurement technique. Quantitative magnetic resonance neurography biomarkers: Cross-sectional results from a single center study in 80 subjects with symptomatic or asymptomatic hereditary transthyretin amyloidosis Assessment of the clinical value of whole-body MRI in untreated patients with systemic light chain amyloidosis
3:05 PM	4:10 PM	4. Scientific Session		AL Amyloidosis mouse model ATTR mouse model AL C. elegans model
4:10 PM	4:30 PM	Break		
4:30 PM	6:00 PM	Satellite Symposium - Janssen		Navigating the patient journey in AL amyloidosis: a multidisciplinary approach tbc
6:00 PM	7:00 PM	Satellite Symposium Pfizer		How can one solution solve the multifaceted challenges of ATTR amyloidosis tbc

7:05 PM	8:05 PM	Merlini Award Ceremony		Palladini, Giovanni			
				Westermark, Per			
Tuesday, 6th Sept. 2022							
7:30 AM	8:30 AM	Satellite Symposium Prothena		Addressing the Unmet Need in Advanced AL Amyloidosis: Key Insights from a Panel of Experts		tbc	
8:30 AM	10:05 AM	5. Scientific Session	09:30 AM - 5:00 PM Industry Exhibition	AL - Clinical aspects	Kumar, Shaji		
				Sanchorawala, Vaishali			
				Gustine, Joshua		Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: a 25-year longitudinal study	
				Staron, Andrew		The prognostic importance of flow cytometry-based measurable residual disease (MRD) in patients with systemic light chain amyloidosis	
				Fotlou, Despina		Prognostic Impact of Translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies	
				de Frutos, Fernando	O	Incidence and risk factors of sudden death in patients with cardiac amyloidosis.	
				Milani, Paolo	A	Clonal features affect survival of patients with non-cardiac light chain (AL) amyloidosis: a European study of 386 patients	
				Milani, Paolo		Light chain deposition disease: an international study in 523 patients	
				Dittrich, Tobias		Elotuzumab in combination with IMiDs for AL amyloidosis patients with relapsed/refractory plasma cell dyscrasia and advanced organ involvement	
				Chakraborty, Rajshekhar		First Report on Outcome of Patients with Newly Diagnosed Stage IIb Cardiac Light Chain Amyloidosis Treated with Daratumumab-based Frontline Therapy	
10:05 AM	10:30 AM	Break					
10:30 AM	12:05 PM	6. Scientific Session	09:30 AM - 5:00 PM Industry Exhibition	Basic Research - New treatment targets and biomarkers	Morgan, Gareth		
				Fernandez, Carlos		Collagen associated with AL amyloid inhibits fibril phagocytosis - Collagen degradation renders amyloid sensitive to uptake by the innate immune system	
				Jackson, Joseph W.		In-vitro ultrasonic assay indicates importance of extracellular chaperon-like effect of serum albumin to protect dialysis patients from dialysis-related amyloidosis	
				Nakajima, Kichitaro		Dissecting FAM46C-dependent tuning of antibody secretion in systemic AL amyloidosis.	
				Milan, Enrico	O	Development of novel human chimeric antigen receptor-macrophages (CAR-M) as a potential therapeutic for amyloid clearance	
				Balachandran, Manasi	A	Preclinical characterization of AT-02, a pan-amyloid-binding immunoglobulin-peptide fusion protein capable of inducing enhanced phagocytosis of amyloid	
				Wall, Jonathan		Regulation of BCL2 family members by microRNA-9 and microRNA-181a in AL amyloidosis	
				Fishov, Hilla		Elevated fibrosis associated biomarkers in ATTR amyloidosis patients are associated with impaired cardiovascular outcome.	
				Hein, Selina Julia		Targeting protein secretion as a therapeutic strategy in AL amyloidosis.	
				Moscvin, Maria			
12:05 PM	1:15 PM	Lunch & Poster Viewing		Poster Viewing: Basic science and Imaging			
1:15 PM	2:30 PM	7. Scientific Session		AA - Clinical aspects	Blank		
					Georgin-Lavialle	AA Amyloidosis in Europe, Perspectives and Challenges	
					Khellaf, Ghalia	AA Amyloidosis in Africa, Perspectives and Challenges	
					Kvackay, Peter	Tocilizumab can prevent the progression of renal AA amyloidosis to end stage renal disease	
					Joshi, Tracy	Natural history and risk stratification of AA amyloidosis based on a 40-year experience in the United States	
					Wien, Tale Norbye	Long-term transplant outcomes in recipients with renal amyloidosis.	
2:30 PM	3:30 PM	Satellite Symposium Bridge Bio		Improving patient outcomes in ATTR-CM		tbc	
3:30 PM	5:00 PM	Satellite Symposium Ionis		Optimizing Multidisciplinary Care in Patients With ATTR		tbc	
5:00 PM	7:00 PM	Free Time / Explore Heidelberg					
7:00 PM	7:30 PM	Poster Viewing	Get together	Late breaking abstracts			
7:30 PM	8:15 PM			Case Presentation (Round table)	Sanchorawala, Vaishali		
					Cibeira, Maite		
					Milani, Paolo		
					tbc		
8:15 PM	9:15 PM			Juniors meet Seniors (Round table)	aus dem Siepen, Fabian		
					Riva, Eloisa		
					Westermark, Per		
					Lentzsch, Suzanne		
					Weyand, Cornelia		
					tbc		
					Grogan, Martha		
					tbc		
					Students		
Wednesday, 7th Sept. 2022							
7:45 AM	8:30 AM	Satellite Symposium Sobi™		Expert Discussion: Is Disease Remission in hATTR a Realistic Goal?		tbc	
8:30 AM	10:05 AM	8. Scientific Session	09:30 AM - 5:00 PM Industry Exhibition	ATTRv - Clinical aspects	Adams, David		
				Waddington-Cruz, Martha			
				Wixner, Jonas		Patisiran Global Open-label Extension Study at 36 Months: Effect of Long-term Treatment on Mortality and Ambulatory Function in Patients with hATTR Amyloidosis with Polyneuropathy	
				Takahashi, Yusuke		Progression and distribution pattern of cerebral amyloid angiopathy in hereditary ATTR amyloidosis patients visualized by 11C-PIB-PET imaging	
				Obici, Laura		An international Delphi survey for the definition of a multidisciplinary holistic approach to the care of hereditary ATTR amyloidosis	
				Coelho, Teresa	O	Eplontersen in ATTR-polyneuropathy: results from the 35-week interim analysis of NEURO-TTransform	
				Wixner, Jonas	A	Diflunisal treatment for hereditary transthyretin amyloidosis – the Swedish DFNS-02 trial	
				Campos, Andrea		Kidney phenotype and immune activation in hereditary ATTR amyloidosis during inotersen therapy	
				Appiah-Kubi, Kwaku		Association of hereditary V122I amyloidogenic transthyretin variant with heart failure: A systematic review and meta-analysis	
				Gonzalez-GiDuarte, Alejandra		Tafamidis reduces skin denervation and amyloid in skin biopsies of very early symptomatic hATTRv patients after one year of treatment	
9:00 AM	10:00 AM	ISA-EHA Session		Better understanding and Targeting the clone in AL Amyloidosis	Kastritis, Efsthios		
					Minnema, Monique		

					Rossi, Davide		Marginal zone lymphoma and M. Waldenström
					Raab, Marc		Future MM therapies suitable for AL
10:05 AM	10:30 AM	Break					
10:30 AM	12:05 PM	9. Scientific Session	09:30 AM - 5:00 PM Industry Exhibition	Pathways to diagnosis	Naiki, Hironobu		
					Amann, Kerstin		
					Delbarre, Marc-Antoine		Automated cardiac amyloidosis risk detection on whole body bone scintigraphy using deep-learning approach
					Naiki, Hironobu		Establishment of the nation-wide pathology consultation system for the typing diagnosis of amyloidosis in Japan: Steep increase in the number of transthyretin-positive cardiac biopsy cases
					Gottwald, Juliane		The amyloid proteome: a two-way approach for a protein classification system
					Kimmich, Christoph Richard	O	Fat aspiration as a screening tool for symptomatic systemic amyloidosis - sensitivity and specificity analysis with better sensitivity results for females with all major subtypes
					Fabris, Francesca	A	Sequence of diagnostic testing in cardiac amyloidosis patients: early monoclonal protein study is associated with better outcomes in AL amyloidosis.
					Amadio, Jennifer Marie		Artificial intelligence modeling for earlier identification of cardiac amyloidosis.
					Beck, Hans Christian		A novel mass spectrometry-based method for the identification of subtype specific amyloidogenic proteins from fat aspirates
					Mangiacavalli, Silvia		Pre-symptomatic diagnosis of systemic AL amyloidosis by biomarker based screening in patients with MGUS
12:05 PM	1:20 PM	Lunch & Poster Viewing		Pathway to diagnosis, Innovative drugs and non-AL / non-ATTR amyloidosis			
1:20 PM	3:00 PM	10. Scientific Session		Basic research - Amyloid fibril formation including proteolysis and tissue interactions	Schmidt, Matthias		
					Röcken, Christoph		
					Schönland, Stefan		
					Schmidt/Schönland/Röcken		
					Pradhan, Tejaswini		Kinetics of the aggregation process of the human λ -III immunoglobulin light chain FOR005 involved in AL amyloidosis at atomic resolution
					Schulte, Tim		The ex vivo cryo-EM structure of AA amyloid from a domestic short hair cat
					Speranzini, Valentina		The interplay between protein dynamics and proteolysis in LC amyloid aggregation
					Tiiman, Ann	O	Time-resolved nano-spectroscopy with single-molecule sensitivity for blood-based non-immune diagnosis of amyloid diseases
					Bezerra, Filipa	A	In vitro and in vivo effects of SerpinA1 on the modulation of transthyretin proteolysis
					Gu, Xiaohong		AA amyloid-containing diet potentiates A β 42 induced effects in transgenic <i>Drosophila melanogaster</i>
					Jiang, Xin		Dichotomy of Circulating Non-native TTR (NNTR) Levels in Polyneuropathy and Cardiomyopathy Patients Provides a Glimpse to ATTR Tissue Specificity
					Louros, Nikolaos		Heterotypic amyloid interactions and their effect on amyloid assembly
3:00 PM	4:30 PM	Satellite Symposium Alexion		Beyond Survival-How Emerging Treatments May Improve Life for Patients with AL Amyloidosis			tbc
4:30 PM	5:00 PM	Break / Speaker Corner					
5:00 PM	6:30 PM	Satellite Symposium Alnylam		Meeting the needs of patients with hATTR amyloidosis: innovation in practice			tbc
7:30 PM		Award Ceremony	Get Together				
Thursday, 8th Sept. 2022							
7:45 AM	8:30 AM	Satellite Symposium Attralus		Rationale and unmet need for anti-amyloid therapy in systemic amyloidosis			tbc
8:30 AM	10:00 AM	11. Scientific Session	09:30 AM - 1:00 PM Industry Exhibition	Best abstracts (including late breaking)	tba		
					tba		
					Gatt, Moshe		Feasibility of a novel academic BCMA-CART (HB10101) for the treatment of relapsed and refractory AL amyloidosis
					Charalampous, Charalampous		A Proteomic Atlas of Renal Amyloid Plaques Provides Insights Into Disease Pathogenesis
					Saelices, Lorena	O	Cryo-EM study of cardiac ATTR fibrils and structure-based development of detection probes and anti-seeding inhibitors
					Basset, Marco	A	An European collaborative study on 476 patients with AA amyloidosis: identification and validation of survival and renal staging systems
					tbc		
					tbc		
10:00 AM	10:30 AM	Break / Speaker Corner					
10:30 AM	12:00 PM	12. Scientific Session (Round Table)		Translation - How to close the gap of basic and clinical research in AL and ATTR	Schönland, Stefan		
					Belotti, Vittorio		
					Ramirez-Alvarado, Marina		
					Schymkowitz, Joost		
					Wall, Jonathan		
					Wixner, Jonas		
					Jaccard		
12:00 PM	12:45 PM	Membership Meeting			Palladini, Giovanni		
12:45 PM	1:00 PM	Closing Ceremony					

Program is subject to modification.